PetVivo Holdings, Inc. (PETV): Termination of a Material Definitive Agreement
PetVivo Holdings, Inc. (PETV) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 TERMINATION AND SETTLEMENT AGREEMENT — VetStem, Inc. / PetVivo Holdings, Inc. — CONFIDENTIAL Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) the type of information that the r
How this was made
The 30-second read
Why it matters
The agreement terminates the exclusive license, ends PetVivo’s sales rights immediately, and transfers specified remaining inventory to VetStem at no cost. It also sets a one-time settlement payment schedule from PetVivo to VetStem and removes any sell-through period.
Market read
For PETV traders, the key change is the loss of exclusive license rights and immediate cessation of sales, which can materially alter near-term revenue expectations.
What to watch
The exhibit references prior amendments and disputes; without the full financial terms of the original license, the net impact on expected cash flows could be smaller than implied by the termination alone.
Background
PetVivo and VetStem previously entered an Exclusive License and Supply Agreement (Feb 13, 2025) with amendments, and the parties now resolve disputes by terminating the relationship.
Ticker impact
PetVivo filed an 8-K stating it terminated a material definitive license and supply agreement with VetStem, including inventory transfer and sell-through ending.
Near-term downside bias from reduced commercial rights, partially offset by a one-time $75,000 settlement payment.
The filing explicitly ends the exclusive license, stops PetVivo sales on the effective date, and transfers remaining inventory to VetStem, which is typically revenue-negative. The agreement also includes a defined $75,000 payment, which can cushion cash impact but is small relative to typical public-company valuation.
Market effects
Could signal heightened counterparty risk or commercialization fragility in niche veterinary pharma licensing models, but no broader sector datapoint is provided.
No clear regional spillover described.
No global market linkage beyond the specific license termination.
Counterpoint
The $75,000 settlement plus inventory transfer could reduce ongoing operational burden and litigation/contract uncertainty, potentially improving balance-sheet clarity.
Key entities
- issuerPetVivo Holdings, Inc.
Subject of the 8-K, the licensee whose exclusive rights and sales are terminated under the agreement.
- counterpartyVetStem, Inc.
Licensor under the terminated exclusive license and supply agreement; receives inventory and settlement payment per the agreement.
